Novo Nordisk Launches Esperoct [antihemophilic factor (recombinant), glycopegylated-exei] to Treat
Shots: Novo Nordisk reports the availability of Esperoct in the US to treat adults and children with hemophilia A as it replaces the clotting Factor VIII that people with hemophilia A are missing and maintains Factor VIII levels longer which help in reducing the frequency of bleeding with less frequent dosing In 2019, Esperoct has […]Read More